Reporting Health-Related Issues Involving Cosmetics, Drugs and Medical Devices to the FDA
A practical guide for American consumers, patients, caregivers and health professionals—and for foreign manufacturers, exporters and brand owners preparing to respond when an FDA-regulated product is associated with an adverse event, quality defect, medication error, device malfunction or therapeutic failure in the United States.
Why Adverse-Event Reporting Matters
Consumers and health professionals are often the first people to recognize that an FDA-regulated product may be causing harm or failing to perform safely. A patient may develop a serious rash after using a cosmetic, experience unexpected bleeding after beginning a medicine, suffer an injury when a medical device malfunctions, or discover that product labeling is confusing or incorrect. A single report may appear isolated, but when FDA receives similar reports from multiple sources, the combined information may reveal a safety signal that was not visible during product development or premarket review.
FDA’s MedWatch program is the agency’s principal gateway for receiving voluntary reports about serious problems involving human medical products. Consumers, patients, caregivers and health professionals may report suspected adverse events, product quality problems, product-use or medication errors, therapeutic failures and device malfunctions. The person filing a voluntary report does not have to prove that the product caused the problem. The report should describe what happened, identify the suspected product and clearly distinguish facts from assumptions.
For foreign manufacturers, exporters and brand owners, a U.S. adverse-event report can quickly become a regulatory, commercial and reputational matter. Information may reach the company through a distributor, hospital, importer, retailer, online marketplace, social-media post, attorney, insurer or FDA. Companies that lack complaint procedures, traceability, medical review, regulatory assessment and recall readiness can lose valuable time. U.S. FDA Consultants can help foreign companies establish reporting systems, assess mandatory obligations, coordinate with U.S. importers and agents, prepare FDA submissions, investigate root causes and document corrective actions.
What Is FDA MedWatch?
MedWatch is FDA’s safety information and adverse-event reporting program for human medical products. It supports postmarket surveillance by collecting reports that may identify previously unrecognized risks, changes in the frequency or severity of known risks, manufacturing or quality problems, confusing labeling, preventable use errors and product failures.
Voluntary reports can involve prescription medicines, over-the-counter drugs, therapeutic biologics, medical devices, combination products, cosmetics, cannabinoid hemp products and certain other FDA-regulated products. FDA safety evaluators review reports together with other available information. A report may contribute to label changes, safety communications, product corrections, recalls, inspections or additional studies.
The existence of a report does not establish causation. A symptom may be related to an underlying disease, another product, improper use or an unrelated event. Nevertheless, well-documented reports are valuable because they allow FDA to evaluate patterns and generate hypotheses that can be investigated further.
What Problems Should Consumers and Health Professionals Report?
Adverse Events
Unexpected side effects, allergic reactions, injuries, hospitalization, disability, congenital anomalies, life-threatening events or death suspected to be associated with a product.
Quality Problems
Contamination, broken seals, abnormal color or odor, defective packaging, incorrect labeling, device defects, missing components or products that do not meet expected specifications.
Use Errors and Failures
Look-alike packaging, confusing names, unclear instructions, incorrect device displays, preventable medication errors, therapeutic inequivalence or failure to perform as expected.
A consumer should consider reporting when a product problem causes harm, could cause harm if repeated, or indicates a significant defect. A medical device malfunction can be important even when no one was injured, especially when recurrence could result in death or serious injury. Health professionals should report clinically significant suspected associations even when causation has not been proven.
How Consumers and Patients Can Report
Consumers and patients may submit a voluntary report through MedWatch Online. FDA also provides Form 3500B, a consumer-friendly form designed for patients and caregivers. Reports may be submitted online or by following the current mailing or fax instructions provided by FDA.
Get Medical Help
Contact a physician, pharmacist, poison-control center or emergency service as appropriate. Do not delay treatment while preparing a report.
Preserve Evidence
Keep the product, packaging, receipt, instructions, lot number, expiration date, serial number, Unique Device Identifier and photographs.
Document the Timeline
Record when the product was started or used, when symptoms began, what treatment was provided and whether the problem improved after use stopped.
Submit Complete Facts
Identify the product and manufacturer as precisely as possible, describe the event in plain language and provide contact information for follow-up.
Guidance for Physicians, Pharmacists and Other Health Professionals
Health professionals provide especially valuable reports because they can document objective findings, differential diagnoses, treatment, laboratory data and clinical outcomes. A strong report should identify the patient without using unnecessary personal identifiers, describe the suspected product, explain the chronology and include relevant medical history and concomitant products.
Clinicians should avoid overstating causation. “Symptoms began two days after treatment started and resolved after discontinuation” is more useful than an unsupported statement that the product definitively caused the event. Relevant negative findings should also be included because they may help FDA evaluate alternative explanations.
Health professionals should provide follow-up information when available, including hospitalization records, pathology, laboratory results, device evaluation, rechallenge or dechallenge information and final outcomes. Voluntary reporting may be particularly important for rare events, unusual severity, medication errors, product-quality defects and device malfunctions that might recur.
Information to Include in a MedWatch Report
Form FDA 3500 contains sections for patient information, the event or product problem, product availability, suspect drugs or biologics, suspect medical devices, concomitant products and reporter information. FDA Form 3500B uses simpler language for consumers and patients. Online reporting is generally the fastest route.
Reporting Cosmetic Product Problems
Consumers and health professionals may report cosmetic product complaints involving burns, infections, allergic reactions, hair loss, eye injuries, respiratory effects, contamination, labeling problems, unusual odors, foreign material or other adverse events. FDA currently directs cosmetic complaints through its applicable complaint and adverse-event reporting channels, including MedWatch and the Food and Cosmetics Information Center.
Under the Modernization of Cosmetics Regulation Act of 2022, the “responsible person” for a cosmetic product has mandatory duties when it receives a report of a serious adverse event associated with use of the product in the United States. The responsible person must generally submit the serious adverse-event report to FDA within 15 business days and include a copy of the product label. New medical or other information received within one year of the initial report may also have to be submitted within 15 business days.
Foreign cosmetic manufacturers should define which U.S. entity is the responsible person, how complaints reach that entity, how seriousness is assessed, how labels and records are retrieved and who submits reports. Complaint records should be retained and available for FDA inspection as required.
Reporting Drug and Therapeutic Biologic Problems
MedWatch accepts reports involving prescription drugs, over-the-counter medicines, compounded drugs, therapeutic biologics and combination products. Reportable concerns may include unexpected reactions, serious known reactions with unusual severity, medication errors, lack of expected effect, contamination, incorrect strength, defective packaging, labeling confusion or suspected counterfeit products.
Consumers should include the product name, dosage, route, treatment dates, indication, lot or NDC when available and whether the reaction improved after the product was stopped. Health professionals should include concomitant medicines, relevant disease history, laboratory data and treatment.
Manufacturers, packers and distributors may have mandatory postmarketing reporting duties under product-specific statutes, regulations, applications and licenses. Foreign drug establishments should not rely solely on a U.S. distributor to recognize and submit all required reports. Contracts and pharmacovigilance agreements should clearly assign intake, medical review, case processing, expedited reporting, follow-up and recordkeeping responsibilities.
Reporting Medical Device Problems
Consumers, patients and health professionals may voluntarily report medical-device deaths, serious injuries, malfunctions, labeling errors, use errors and quality problems through MedWatch. Reports should identify the brand, common device name, manufacturer, model, lot, catalog number, serial number, expiration date and Unique Device Identifier when available.
Important contextual facts include who operated the device, whether it was implanted or explanted, whether it was serviced, whether it was a reprocessed single-use device and whether the product remains available for evaluation. Photos can be useful, but reporters should not send the physical device to FDA unless instructed.
Mandatory Medical Device Reporting under 21 CFR Part 803 applies to manufacturers, importers and device user facilities. Manufacturers generally report deaths, serious injuries and certain malfunctions within 30 calendar days after becoming aware of a reportable event. Certain events requiring prompt remedial action or specifically requested by FDA may require a 5-day report. Importers and user facilities have separate obligations and recipient requirements.
Voluntary and Mandatory Reporting Are Not the Same
| Reporter | Typical form or system | General obligation |
|---|---|---|
| Consumer, patient or caregiver | MedWatch Online or Form 3500B | Voluntary reporting of suspected adverse events and product problems. |
| Health professional | MedWatch Online or Form 3500 | Voluntary unless another law, program or institution imposes a duty. |
| Cosmetic responsible person | FDA serious cosmetic adverse-event reporting process | Mandatory serious-event reporting, generally within 15 business days. |
| Medical-device manufacturer | Electronic MDR / Form 3500A framework | Mandatory death, serious-injury and qualifying malfunction reports, usually within 30 days; some within 5 days. |
| Device importer or user facility | Electronic MDR requirements | Mandatory duties vary by reporter type and event. |
| Drug or biologic applicant/manufacturer | Product-specific electronic safety reporting | Mandatory postmarketing reporting under applicable regulations and approvals. |
Submitting a voluntary report does not necessarily satisfy a company’s mandatory obligation. Industry must evaluate the applicable legal framework, reporter identity, seriousness, expectedness, causality standard, product category, event type and deadline.
What Happens After FDA Receives a Report?
FDA safety reviewers may assess the report, request follow-up information, compare it with similar cases, consult product specialists, inspect a facility, review manufacturing records or evaluate whether a broader signal exists. A single report does not automatically trigger a recall or prove that the product caused the event.
Possible regulatory outcomes include continued monitoring, requests for information, safety communications, labeling changes, manufacturing corrections, field actions, recalls, import controls, inspection findings, warning letters, registration suspension in qualifying cosmetic circumstances or other enforcement action.
Companies should not dismiss a report merely because causation is uncertain. They should preserve records, identify affected lots, evaluate severity and recurrence, perform a documented investigation and decide whether additional reporting or corrective action is required.
Why Foreign Manufacturers and Exporters Need a U.S. Complaint Program
A foreign manufacturer may first learn of a U.S. event through an Amazon message, distributor email, hospital complaint, return request, online review, U.S. Agent communication or FDA inquiry. Time-zone differences, language barriers and unclear contracts can delay escalation.
An effective U.S. complaint program should define intake, translation, medical review, seriousness assessment, reportability, case follow-up, product return, sample preservation, lot traceability, trend analysis, corrective action and record retention. It should identify who is available outside normal business hours and how urgent events are escalated.
Foreign companies shipping cosmetics, drugs, medical devices, food products or other FDA-regulated goods to the United States should ensure that their U.S. Agent, importer, initial importer, responsible person, distributor and brand owner understand their respective roles. Titles that sound similar can carry very different legal responsibilities.
Services Provided by U.S. FDA Consultants
Complaint Procedures
Drafting SOPs for complaint intake, triage, medical escalation, investigation, reporting, trend analysis and closure.
Reportability Assessments
Helping evaluate voluntary MedWatch, cosmetic serious adverse-event, MDR and product-specific reporting obligations.
FDA Submission Support
Organizing case facts, product identifiers, narratives, follow-up information and supporting documentation.
Root-Cause Investigations
Reviewing manufacturing, labeling, supplier, quality, distribution and service records to identify probable causes.
Recall Readiness
Preparing recall procedures, consignee lists, communication templates, effectiveness checks and mock-recall exercises.
FDA Response Assistance
Supporting document requests, inspections, corrective-action plans, importer coordination and regulatory correspondence.
A consultant cannot replace emergency medical treatment, the company’s legal responsibility or specialized legal counsel. The consultant can help build a disciplined compliance process, reduce avoidable delays, improve records and coordinate a credible response.
Preventive Compliance Services Before an Event Occurs
U.S. FDA Consultants can review facility registration, product listing, U.S. Agent arrangements, cosmetic responsible-person obligations, device initial importer requirements, labeling, claims, quality systems, adverse-event procedures, recall plans and complaint records before a product enters the U.S. market.
For medical devices, preventive work may include MDR procedures, complaint files, UDI review, device listing, Quality Management System readiness and importer responsibilities. For cosmetics, it may include MoCRA facility registration, product listing, label review, safety substantiation, adverse-event records and recall readiness. For drugs, it may include establishment registration, drug listing, labeling, pharmacovigilance interfaces and import documentation.
Foreign food manufacturers and exporters can also benefit from complaint programs, recall plans, FSVP support, label review, food facility registration and U.S. Agent services. Although food complaints use different reporting routes, the same principles of traceability, timely escalation, documented investigation and corrective action apply.
Common Mistakes That Increase Regulatory Risk
- Assuming that only confirmed causation should be reported.
- Failing to preserve packaging, lot numbers, serial numbers, UDI data or returned products.
- Confusing voluntary MedWatch reporting with mandatory industry reporting.
- Missing a 15-business-day cosmetic deadline or a 5- or 30-day MDR deadline.
- Using incomplete narratives that omit timing, treatment, outcome or concomitant products.
- Failing to submit follow-up information when new medical facts become available.
- Allowing distributors, marketplaces and customer-service vendors to hold complaints without escalation.
- Sending inconsistent explanations from the manufacturer, importer, brand owner and U.S. Agent.
- Closing a complaint without a documented investigation or reportability decision.
- Treating adverse-event records as ordinary customer-service correspondence.
Accurate Reporting Supports Safer Products
American consumers, patients and health professionals provide essential information to FDA’s postmarket safety system. A detailed report can help identify an emerging adverse reaction, defective device, medication error, cosmetic injury, quality problem or therapeutic failure before additional people are harmed.
Reporters should seek medical care first, preserve the product and packaging, document the timeline and submit complete facts through the appropriate FDA channel. They do not need to prove causation, but they should clearly describe what they observed and what remains uncertain.
Foreign manufacturers and exporters should treat every credible U.S. complaint as a potential safety and compliance signal. A prepared company can determine its obligations, retrieve records, investigate the cause, communicate consistently and implement corrective action. An unprepared company may lose critical time while affected products remain in distribution.
Prepare Your Company Before an Adverse Event Becomes a Regulatory Crisis
U.S. FDA Consultants can assist foreign manufacturers, exporters, brand owners, U.S. Agents, importers and distributors with adverse-event procedures, complaint files, FDA reporting assessments, MoCRA compliance, Medical Device Reporting, labeling review, recall readiness, root-cause investigations, corrective actions and responses to FDA inquiries.
Do not wait until a consumer reports hospitalization, a device malfunction causes injury, a cosmetic product triggers a serious reaction or FDA requests records. Establish a documented U.S. postmarket complaint and reporting program before products enter commerce.
Section A — Patient Information
- A1 Patient Identifier Use initials or patient code (no full names/SSN).
- A2 Age / DOB Provide DOB or best estimate. (Years if ≥ 3 yrs, months if < 3 yrs, days if < 1 month).
- A3 Sex Sex at birth.
- A4 Weight Weight in lbs or kg (best estimate if unknown).
- A5 Ethnicity Reported ethnicity.
- A6 Race Select all that apply. Do not guess.
Section B — Adverse Event / Problem
- B1 Type of Report Adverse Event, Product Problem, or Medication Error (suspicion of association accepted).
- B2 Outcome Attributed Death, Life-threatening, Hospitalization, Disability, Congenital anomaly, Intervention required, or Other serious event.
- B3 Date of Event First onset date (or DOB for congenital anomaly).
- B4 Date of Report Submission date.
- B5 Describe Event Narrative of status beforehand, signs/symptoms, treatment, and outcome.
- B6 Tests / Lab Data Relevant test results (remove confidential info).
- B7 Other History Pre-existing conditions (e.g., hypertension, pregnancy, allergies).
Section C & F — Availability & History
- C1 Product Availability Is product/device available? Note return date if sent to manufacturer.
- C2 Product Picture Indicate Yes/No. Do not mail physical products to FDA.
- F1 Concomitant Products Other products/drugs/devices used at the time of event (exclude post-event treatments).
Section D — Suspect Products
- D1 Product Info Brand/Generic name, Manufacturer, Strength, NDC#, Lot#.
- D2 Dose & Route Amount, frequency, and route (e.g., 500 mg QID orally).
- D3 Therapy Dates Start and stop dates (or duration if < 1 day).
- D4 Indication Diagnosis/reason for product use.
- D5–D6 Type & Expiration OTC, Generic, Compounded, Biosimilar; Expiration date.
- D7–D8 Dechallenge / Rechallenge Did event abate on stopping/reducing? Did it recur on reintroduction?
Section E — Suspect Medical Device
- E1–E3 Device & Manufacturer Brand name, Common name, Procode, Manufacturer, City & State.
- E4 Identifiers Model #, Lot #, Catalog #, Expiration, Serial #, UDI #.
- E5 Operator Health professional, Lay user/patient, or Other.
- E6–E8 Implant / Reprocess / Service Implant/Explant dates; Single-use reprocessed info; 3rd-party servicer status.
Section G — Reporter
- G1 Contact Info Name, Address, Phone, Email for follow-up.
- G2–G3 Occupation Health Professional (specify specialty) or Non-Health Professional.
- G4 Also Reported To Indicate if reported to manufacturer, distributor, or facility.
- G5 Confidentiality Option to withhold reporter identity from the manufacturer.
These groups are legally required to report certain device-related events under 21 CFR Part 803 (Medical Device Reporting, MDR).
Reporting Requirements
Manufacturers: Must report device-related deaths, serious injuries, and malfunctions that could recur.
Importers: Must report deaths and serious injuries to both the FDA and the manufacturer.
User facilities (Hospitals, Nursing Homes): Must report device-related deaths to the FDA and manufacturer, and serious injuries to the manufacturer (or FDA if manufacturer unknown).
Required Form
Submit FDA Form 3500A (Mandatory Reporters) through the Electronic Submissions Gateway (ESG) or Safety Reporting Portal.
